Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2561-2580 of 3,900 trials

BCG Vaccination: Understanding Immune Response

We are studying how pre-vaccination immune status affects the response to the BCG vaccine. This research may help improve vaccination strategies by identifying key immune factors.

Healthy Participants>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Fibrotic Lung Disease: Wharton's Jelly Stem Cells

We are studying the safety and effects of a stem cell treatment for people with fibrotic interstitial lung diseases. This research aims to see if it can improve lung function and quality of life.

Interstitial Lung Disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesInternal MedicinePulmonology

Epcoritamab for Relapsed Large B-Cell Lymphoma

We are studying the effectiveness of Epcoritamab as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma. This trial aims to see how well it works and how safe it is compared to other treatments.

Diffuse Large B-cell Lymphoma1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Ewing's Sarcoma: Naxitamab Treatment Study

We are evaluating the safety and effectiveness of naxitamab added to standard chemotherapy for patients with refractory Ewing's sarcoma. This study aims to see if this combination can improve treatment outcomes.

Ewing's Sarcoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Low Ovarian Reserve: Factor-Rich Plasma Treatment

We are studying whether Factor-Rich Plasma injections can improve ovarian function and increase pregnancy rates in women with low ovarian reserve. This trial will also monitor any potential complications from the treatment.

Low Ovarian Reserve1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsInternal Medicine

Small Cell Lung Cancer: ZL-1310 Study

We are testing different doses of ZL-1310 in patients with small cell lung cancer. The goal is to find a suitable dose and see how well the body tolerates and processes the medication.

Small Cell Lung Cancer6-12 monthsSafety phase (I)Oncology

Cognitive Dysfunction in Schizophrenia: Clemastine and Exercise Study

We are investigating whether combining Clemastine with aerobic exercise can improve cognitive function in people with schizophrenia. The study aims to see if this approach enhances memory and overall functioning.

Schizophrenia>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPsychiatry

AMG 193 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, AMG 193, for patients with advanced non-small cell lung cancer that has a specific genetic deletion. The trial aims to evaluate its safety and effectiveness compared to existing options.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced NSCLC: MCLA-129 Treatment Study

We are evaluating a new bispecific antibody, MCLA-129, for patients with advanced non-small cell lung cancer. The study aims to assess its effectiveness and safety compared to standard treatments.

Solid TumorsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Lung Cancer: ABBV-400 and Budigalimab Study

We are testing a new treatment combining ABBV-400 and Budigalimab for adults with advanced non-squamous lung cancer who haven't had prior treatment. The goal is to see how safe it is and how well it works.

Advanced Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

New Treatment for Primary CNS Lymphoma: Optimizing MATRix

We are studying a modified treatment approach for patients with newly diagnosed primary CNS lymphoma to see if it improves survival and quality of life compared to standard therapy. This trial aims to find a safer and effective way to induce remission before further treatment.

Primary Central Nervous System Lymphoma (PCNSL)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Wart Treatment: 2LVERU® JUNIOR and 2LVERU®

We are studying whether two new treatments can help people with warts get rid of them more effectively than a placebo. The trial will also look at pain levels and safety during treatment.

Warts>2 yearsConfirmation phase (III)Monitoring phase (IV)Standard MedicinesDermatologyInfectious Diseases

Breast Cancer: Shorter Hormone Therapy Duration

We are studying whether limiting hormone therapy to 2 years is effective for women with hormone-sensitive breast cancer at very low risk of recurrence. This trial aims to assess the safety and quality of life during and after treatment.

Localized Luminal A Breast Cancer in Post-Menopausal Women>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOncology

Giant Cell Arteritis and Rheumatoid Arthritis: PET/CT Imaging Study

We are testing a new imaging method to see inflamed arteries in giant cell arteritis and inflamed joints in rheumatoid arthritis. This study aims to improve how we visualize and understand these conditions.

Giant Cell ArteritisRheumatoid Arthritis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyRheumatology

Compulsive Sexual Behavior Disorder: Medication Study

We are comparing the effects of escitalopram, naltrexone, and their combination on symptoms of compulsive sexual behavior. This study aims to understand how these treatments may improve daily functioning and emotional well-being.

Compulsive Sexual Behavior3-6 monthsConfirmation phase (III)Investigational MedicinesPsychiatry

Giant Cell Arteritis: Imaging Study with [18F]fluor-PEG-folate

We are investigating how well a special imaging technique shows changes in arteries of patients with giant cell arteritis before and after treatment. This may help us understand the disease better and improve future care.

Giant Cell Arteritis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementRheumatology

Severe Autoimmune Encephalitis: Bortezomib Study

We are investigating whether bortezomib is effective and safe for patients with severe autoimmune encephalitis. This trial focuses on individuals with specific autoantibodies related to their condition.

Autoimmune Encephalitis3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementNeurologyRheumatology

Focal Onset Seizures: Extended-Release Levetiracetam Study

We are testing a new once-daily version of levetiracetam for people with drug-resistant focal onset seizures. The study aims to see if it reduces seizure frequency better than current treatments and a placebo.

Refractory Epilepsy3-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Duchenne Muscular Dystrophy: SGT-003 Gene Therapy

We are studying a new gene therapy to see if it is safe and effective for males with Duchenne Muscular Dystrophy. The trial will assess improvements in muscle function and other health measures after a single intravenous dose.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Psoriatic Arthritis and Axial Spondyloarthritis: Sonelokimab Study

We are exploring how sonelokimab affects disease activity in patients with active psoriatic arthritis or axial spondyloarthritis. This study will help us understand its potential benefits and safety.

Axial SpondyloarthritisPsoriatic Arthritis3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineRheumatology